BioCryst Pharmaceuticals, Inc. (BCRX)
7.41
-0.17
(-2.24%)
USD |
NASDAQ |
Dec 12, 12:52
BioCryst Pharmaceuticals Cash from Investing (Quarterly): 13.57M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Astria Therapeutics, Inc. | 52.25M |
| Hologic, Inc. | -132.10M |
| Johnson & Johnson | -542.00M |
| Viatris, Inc. | -98.90M |
| KalVista Pharmaceuticals, Inc. | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 41.11M |
| Cash from Financing (Quarterly) | -58.30M |
| Free Cash Flow | 47.64M |
| Free Cash Flow Per Share (Quarterly) | 0.1809 |
| Free Cash Flow to Equity (Quarterly) | 95.58M |
| Free Cash Flow to Firm (Quarterly) | 60.67M |
| Free Cash Flow Yield | 2.98% |